CRISPR Therapeutics AG — Director's Dealing 2018

Aug 3, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2018-08-01

Reporting Person: Ho Tony W (See Remarks)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-08-01	Common Shares	M	37500	—	Acquired	37500	Direct
2018-08-02	Common Shares	F	14631	$48.43	Disposed	22869	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-08-01	Restricted Stock Units	$	M	37500	Disposed		Common Shares (37500)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F2: On August 1, 2017, the reporting person was granted 75,000 restricted stock units that vest in two equal annual installments on 8/1/2018 and 8/1/2019.